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Abstract
Drug-induced cardiotoxicity is a major adverse effect that has been encountered for some 
clinically important drugs especially antineoplastic agents. This toxicity has previously 
led to the post-marketing withdrawal of numerous pharmacologically active drugs and 
limits the efficacy of other clinically useful ones. Currently, assessing the cardiotoxicity 
potential is a crucial parameter in drug development, and many models have been estab-
lished to facilitate its prediction to avoid such toxicity. In this chapter, we will briefly 
discuss the mechanism of drug-induced cardiotoxicity, risk factors, how to prevent, early 
detection and/or management from a pharmacological and toxicological point of view.
Keywords: doxorubicin, oxidative stress, mitochondrial dysfunction, risk prediction, 
biomarkers
1. Introduction
Drug-induced cardiotoxicity is an important cause of attrition of compounds in preclinical 
and clinical development. It represents one of the most serious side effects associated with 
novel drug development, and it is known to be one of the major toxic effects induced by 
several types of drugs [1]. Cardiotoxicity is not restricted to anticancer agents, and almost 
all therapeutic drug classes have unanticipated cardiotoxicities. However, cardiotoxicity 
induced by chronically administered drugs, such as neurologic/psychiatric agents and anti-
cancer chemotherapeutic agents, represents a major problem because toxicity may become 
evident only after long-term accumulation of the drug or its metabolites [2]. Assessing drug-
induced cardiotoxicity risk including QT interval prolongation is considered nowadays an 
integral part of the standard preclinical evaluation of new chemical entities as defined by the 
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International Conference of Harmonization Expert Working Group for all drugs in develop-
ment [3]. Strikingly, almost 10% of drugs in the last four decades have been recalled from 
the clinical market worldwide due to cardiovascular safety concerns, e.g., rofecoxib, tegas-
erod, and sibutramine, and despite the great efforts to reveal cardiotoxicity in the preclinical 
phase of development of medicinal products, cardiotoxicity continues to lead safety concerns 
mainly because of lack of sufficient knowledge of the mechanisms of cardiotoxicity [4].
Currently, cancer is shown to affect more than one in three people in their lifetime, and along 
with cardiovascular disease, they are the two leading causes of death in developed nations. 
Thanks to improvement in cancer pharmacotherapy, a current overall 10-year cancer survival 
stands at 50% across the 20 most common malignancies with a concomitant increase in aware-
ness of the adverse cardiac effects of cancer treatment itself [2]. Further, the 5-year survival 
rate of US childhood cancers has increased from around 60% in the mid-1970s to more than 
80%, and according to the data of National Health and Nutrition Examination, long cancer 
survivors die, 33% of them, of heart disease [5, 6]. Similarly, cardiovascular mortality has 
been extensively reported in patients suffering from psychiatric illness, and some antidepres-
sants and antipsychotic drugs have a broad cardiovascular adverse effect profile that can 
lead to cardiovascular complications, especially cardiac arrhythmias, that have sometimes 
been shown fatal even to patients with no previous cardiac disease history. For instance, the 
use of clozapine, the most effective drug for resistant schizophrenia, has been limited due 
to potentially life-threatening adverse effects, including myocarditis and cardiomyopathy. 
Clozapine-induced myocarditis has been linked up to 24% mortality. The coexistence of a 
heart disease complicates the management of mental illness and worsens the illness course, 
and co-occurrence of psychiatric disorders in cardiac patients might affect the clinical out-
come and morbidity [7–9].
Drug-induced cardiotoxicity, commonly in the form of cardiac muscle dysfunction that may 
progress to heart failure, represents a major adverse effect of some common traditional anti-
neoplastic agents, e.g., anthracyclines, cyclophosphamide, 5 fluorouracil, taxanes, as well as 
newer agents such as biological monoclonal antibodies, e.g., trastuzumab, bevacizumab, and 
nivolumab; tyrosine kinase inhibitors, e.g., sunitinib and nilotinib; antiretroviral drugs, e.g., 
zidovudine; antidiabetics, e.g., rosiglitazone; as well as some illicit drugs such as alcohol, 
cocaine, methamphetamine, ecstasy, and synthetic cannabinoids. Most of the affected patients 
had no prior manifestation of the disease [4, 6, 10–12].
Cardiac toxicity of antineoplastic agents includes left ventricular failure, myocardial isch-
emia, QT prolongation, arrhythmias, pericarditis, myocarditis, hypertension, and throm-
boembolism. Asymptomatic diastolic dysfunction, which is a common feature observed in 
many cancer survivors, has been shown to be the earliest noticeable cardiac abnormality 
[12, 13]. Subclinical cardiotoxicity should also be kept in mind, and it is commonly defined 
on cardiac imaging as clinically asymptomatic left ventricular systolic dysfunction with a 
fall in left ventricular ejection fraction by >10% points to a value of less than <50% which is 
commonly used as the decision threshold to define cardiotoxicity [2]. Alternatively, cardiac 
dysfunction related to cancer treatment has been also defined as a decrease in left ventricular 
ejection fraction by ultrasound greater than 10% (from baseline) and with an absolute value 
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less than 53%, confirmed by a repeat examination at 2–3 weeks. Left ventricular ejection frac-
tion between 53 and 73% is considered normal [14]. Clinically manifested cardiotoxic effects 
may occur acutely at any time from the first dose of treatment till 2 weeks after it is terminated 
or chronically that may occur months after termination of treatment [15, 16]. The frequency to 
recognize such complications with cancer patients has significantly increased during the past 
few decades due to increased survival of those patients which has accompanied the advances 
in drug treatment and health care, and early detection of drug-induced cardiotoxicity is of 
pivotal importance to avoid further deterioration of cardiac function [17].
2. Mechanisms
The exact mechanism of antipsychotic-, anthracycline-, or drug-induced cardiotoxicity remains 
unclear, though it is likely to be multifactorial [2, 18]. Understanding the mechanisms of 
anthracycline-induced cardiotoxicity is crucial for effective cardioprotection. Several com-
plex mechanisms have been implicated including formation of iron complexes that can react 
with O
2
 to form •O
2
−, which in turn dismutates to H
2
O
2
 and/or enters the Haber-Weiss reac-
tion, resulting in •OH, or can react with H
2
O
2
 yielding directly •OH; increased production 
of reactive oxygen and reactive nitrogen species; lipid peroxidation; inflammation; induced 
cardiomyocyte apoptosis; interstitial fibrosis; abnormal signaling of epidermal growth factor 
as well as beta-arrestin; inhibition of nuclear topoisomerase II β; induced DNA damage; inhibi-
tion of vascular endothelial growth factor signaling; defective mitochondrial biogenesis; and 
calcium overloading [15, 16, 19–22]. Mitochondria have an essential role in myocardial tissue 
homeostasis, and deterioration in mitochondrial function eventually leads to cardiomyocyte 
and endothelial cell death and consequent cardiovascular dysfunction [4]. The antiretroviral 
nucleoside reverse transcriptase inhibitors, e.g., zidovudine, may cause cardiac mitochondrial 
dysfunction through inhibition of DNA polymerase-gamma and induction of mitochondrial 
DNA mutations leading to cardiomyopathy [23]. Two broad categories of cardiac adverse 
effects are known, functional and structural effects. Noteworthy, seriously altered function 
may be completely dissociated from structural effect, especially at an early stage [24]. Other 
than the functional deterioration, anthracyclines were also shown to damage several major 
structural proteins regulating cardiac muscle contractility including titin, the myofilament 
forming protein that regulates cardiac function leading to systolic and diastolic dysfunc-
tion [12]. In addition, there is a considerable interindividual variability in the susceptibility 
to chronic anthracycline-induced cardiotoxicity; genetic variants were suggested to have an 
impact on the occurrence of drug-induced cardiotoxicity; a potential role for polymorphisms 
in several candidate genes related to the metabolism of anthracyclines, detoxification of free 
radicals, or variations in body iron levels and genetic testing was recommended to reduce 
the incidence of anthracycline-induced cardiotoxicity [10, 21, 25, 26]. Anthracyclines are more 
likely to produce irreversible (type 1 drug-induced cardiotoxicity) microstructural lesions of 
cardiomyocytes leading to necrosis and apoptosis. Noteworthy, reversible (type 2) cardiotoxic-
ity is associated with biological drugs targeting proteins regulating cancer cell proliferation 
which are also necessary for maintenance of cardiovascular homeostasis, and this toxicity can 
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be resolved after completion of therapy or even during its continuation, and overlap as well 
as addition may occur between the types while using multiple potentially cardiotoxic drugs 
[16, 22]. Noteworthy, some authors mention that reversible drug-induced cardiotoxic adverse 
effects are type 1 while irreversible ones are type 2 [2].
3. Risk factors
Patients undergoing chemotherapy have a higher risk of developing cardiovascular complica-
tions (Table 1), and the risk is even greater if there is a history of heart disease or concomitant 
radiotherapy, increasing the incidence of events by 30% compared to the general population 
[5, 27]. The time course of cardiotoxicity varies depending on several factors including patient 
age at time of exposure and the class effect of chemotherapy drugs, where childhood cancer 
survivors experience exponentially rising risk for delayed cardiovascular events while adult 
cardiovascular risk manifests earlier and depends on the number of conventional coexisting 
cardiac risk factors especially hypertension [2]. Patients who have a moderate to high risk 
of developing or are suspected to have cardiotoxicities indicated according to their medical 
history or abnormal imaging and biomarker levels might warrant treatment of risk factors, 
alternative cancer treatment options, and administration of cardioprotectants [28].
Identification of patients at risk of drug-induced cardiotoxicity is currently considered one 
of the main objectives for cardiologists and oncologists to personalize cancer therapy and 
arrange early preventive interventions. It is of key importance to optimize and standardize 
Risk factors for drug-induced cardiotoxicity:
Patient age at time of exposure (below 4 years and old age)
Female gender
Black ethnicity
Class of chemotherapeutic agent
Total cumulative dose
Concomitant radiotherapy/cardiac irradiation
Abnormal cardiac imaging or biomarkers levels
History of heart disease or left ventricular dysfunction
Hypertension
Obesity
Diabetes
Dyslipidemia
Physical inactivity
Smoking
Genetic predisposition
Table 1. Risk factors for drug-induced cardiotoxicity.
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the management of these patients, in a multidisciplinary approach; an integrated approach 
using molecular, imaging, and clinical data may allow the selection of patients at risk of 
developing chemotherapy-related cardiotoxicity. Risk factors also include total cumulative 
dose, Down syndrome, female gender, black ethnicity, age below 4 years, old age, hyper-
tension, obesity, diabetes, dyslipidemia, physical inactivity, smoking, concomitant cardiac 
irradiation, concomitant treatments, previous left ventricular dysfunction or cardiovascular 
comorbidity, and genetic predisposition. However, drug-induced cardiotoxicity may occur 
idiosyncratically without obvious risk factors [6, 12, 22, 27, 29].
4. Prevention and biomarkers
Measurement of cardio-specific biomarkers can be a valid diagnostic tool for early identi-
fication, assessment, and monitoring of cardiotoxicity. Advantages of biomarkers include 
being minimally invasive, less expensive than echocardiography or nuclear techniques, and 
can easily be repeated without irradiation of the patient. Moreover, the interpretation of the 
results does not depend on the expertise of the operator, thus avoiding the possibility of 
interobserver variability [30].
Moreover, there is an increased interest on the most recent noninvasive diagnostic biomark-
ers to early predict and follow up anthracycline-induced cardiotoxicity allowing a potential 
cardioprotective intervention before irreversible damage. Currently, the most important bio-
markers are cardiac troponins, brain natriuretic peptide, and N-terminal fragment of brain 
natriuretic peptide [16, 31]. Persistent elevation of cardiac troponin I concentrations 1 month 
after anthracycline therapy had more cardiac adverse events at 3 years (84%) than patients 
with transient or no cardiac troponin I elevations (37 and 1%, respectively). Similarly, cardiac 
troponin T concentrations are associated with cardiac outcomes in children receiving moder-
ate-dose anthracyclines for high-risk acute lymphocytic leukemia, and elevated concentration 
of N-terminal pro-brain natriuretic peptide during the first 90 days of therapy was associated 
with an abnormal left ventricular thickness-dimension ratio 4 years later, suggesting patho-
logic left ventricular remodeling [6]. Recently, circulating microRNAs are being considered 
to represent promising noninvasive and specific circulating biomarkers of several cardiovas-
cular diseases, and they were successfully tested in children and young adults treated with 
anthracycline chemotherapy [32]. Fatty acid-binding protein 3 is a cytosolic protein found 
primarily in the heart but also in the muscle, brain, and kidney with a primary role in intracel-
lular transport of long-chain fatty acids and in regulation of gene expression via peroxisome 
proliferator activator receptor. It has been demonstrated to be more sensitive than cardiac tro-
ponin for detection of ischemic injury and ongoing cardiac injury associated with congestive 
heart failure [33, 34]. Other less commonly used biomarkers include plasma cystatin-C, galec-
tin-3, interleukin-6, tumor necrosis factor-alpha, and high-sensitivity C-reactive protein [6]. 
Noteworthy, the use of the classical biomarkers of lactate dehydrogenase and creatine kinase 
and their isozymes as biomarkers of cardiotoxicity has been substantially limited due to lack 
of tissue specificity and sensitivity [35, 36]. However, circulating biochemical markers carry 
potential problems related to sensitivity and specificity as they can be significantly influenced 
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by multiple microenvironmental factors and noncardiovascular diseases. Further, troponin 
levels increase in the blood only after tissue damage has occurred, and thus they cannot be 
used as early diagnostic markers of dysfunction onset [2, 32]. Human embryonic stem cell-
derived cardiomyocytes are under investigation to predict drug-induced cardiotoxicity [3].
5-fluorouracil is perhaps the second, after doxorubicin, the most common cause of che-
motherapy-associated cardiotoxicity which occurs predominantly in the first 72 h of the 
initial treatment cycle and may include chest pain, ECG changes, arrhythmia, pulmonary 
edema, myocardial infarction, and, rarely, cardiac arrest. Careful clinical monitoring during 
5-fluorouracil administration in patients with preexisting cardiac disease is important, and 
its administration should be stopped immediately in patients who develop a cardiac adverse 
event. These patients should not be retreated with this agent, as the risk of a subsequent, 
potentially more serious cardiac event increases with repeat exposure [37].
5. Management
Standard management during anthracycline-based chemotherapy involves cardiac function 
assessment prior to treatment, monitoring potential cardiotoxicity during the therapy, as 
well as a long-term follow-up after the chemotherapy is completed [12]. A risk prediction 
model to identify patients at increased risk for therapy-induced cardiac disease prior to start-
ing or during therapy using patient demographics (e.g., age at treatment, gender), treatment 
(e.g., cumulative anthracycline dose, radiation exposure), genomics, serial biomarkers, and 
echocardiographic measurements at baseline and during follow-up is under progress to 
enable investigators with an interest in cardiac late effects resulting from childhood cancer 
treatments to perform further investigation in the field [38].
Cardiac damage initially occurs in a molecular phase, followed by cellular damage, asymp-
tomatic dysfunction, and finally symptomatic clinical dysfunction. The diagnostic intervention 
involves monitoring left ventricular ejection fraction by ultrasound, multigated acquisition 
scan, or MRI, considering <53% as abnormal. Cardiac MRI is considered the reference tech-
nique for quantification of left ventricular ejection fraction. However, ultrasound offers the 
advantages of its availability, low cost, lack of radiation, and overview of cardiac function. 
Yet, 2D ultrasound depends on the quality of the image and the expertise of the operator. 
Furthermore, it has a reported variability of about 10%, similar to the value used for diagnosis 
of cardiotoxicity [39].
Doppler speckle-tracking-derived longitudinal strain echocardiography has been useful in 
assessing adults for cardiac damage, and cardiac MRI has characterized myocardial tissue 
and assessed perfusion abnormalities independent of a good transthoracic window to obtain 
acceptable echocardiographic images [6]. Radionuclide angiography is an alternative method 
to detect cardiotoxic damage, and scintigraphy is also used for heart imaging in oncology, as 
it enables the assessment of left ventricular function [12]. Future improvement in the modali-
ties to early detect drug-induced cardiotoxicity may include advanced techniques in cardiac 
nuclear molecular imaging and photoacoustic imaging [2].
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Some authors have suggested patients receiving cardiotoxic drugs to be regarded as stage 
A heart failure, and if they experience an asymptomatic decline in left ventricular ejection 
fraction, they should be treated as per stage B [40]. Several protocols have been proposed 
to ameliorate or treat doxorubicin-/drug-induced cardiotoxicity including the use of epiru-
bicin which has a less cardiotoxic potential than doxorubicin, reduction of lifetime cumula-
tive dose, avoiding bolus, the use of continuous infusion with reduced peak concentration, 
prolongation of infusion time, the use of non-pegylated liposomal formulation of doxorubicin 
to help more specific delivery to the target site which can further reduce adverse cardiac 
effects, and the concomitant use of the antioxidant and iron chelator dexrazoxane, angioten-
sin-converting enzyme inhibitors, angiotensin receptor blockers, beta blockers, ranolazine, 
metformin, and hydroxymethylglutaryl-coenzyme A reductase inhibitors which have been 
shown to reduce drug-induced cardiotoxicity when used in a prophylactic setting. Further, 
the use of antioxidants, e.g., self-nanoemulsifying formulation of quercetin, Q10 coenzyme, 
vitamin E, and carnitine as well as avoidance of combinations which have an augmented 
cardiotoxic potential like anthracyclines added to trastuzumab would help to reduce the 
likelihood of drug-induced cardiotoxicity [12, 19, 21, 29, 41–43]. Carvedilol beta and alpha 1 
blocker with strong antioxidant properties has been also shown to inhibit anthracycline- and/
or trastuzumab-induced left ventricular dysfunction by ameliorating reactive oxygen spe-
cies formation, mitochondrial alterations, and cardiomyocyte-induced apoptosis. Further, the 
combination of enalapril and carvedilol seemed to be beneficial in treating anthracycline-
induced cardiotoxicity [22]. Additionally, a telemedicine system has allowed interdisciplinary 
management of the patients receiving anthracyclines with an expert cardiologist, and vari-
ous chronoprogrammable drug delivery systems have been developed [2, 44]. Noteworthy, 
dexrazoxane has been reported to augment the myelosuppressive properties of doxorubicin, 
and a hypothetical concern of its possibility to provide a protective benefit to the neoplastic 
cells has resulted in its underutilization [45]. Further, it has been recommended that clozapine 
dose should be titrated gradually (in up to 25 mg/day increments) over 4–6 weeks until the 
target dose is reached as it has been shown that the risk of clozapine-induced myocarditis 
may be increased with a higher cumulative dose early in clozapine titration [18].
Interestingly, epidemiological studies have demonstrated that the incidence of cardiovascular 
disorders in France is strikingly lower than other western countries with a fat-containing 
diet. This so-called French paradox has been attributed to moderate consumption of red wine 
containing the potent antioxidant resveratrol in France, and resveratrol was suggested to be 
used during early cellular damage in organ toxicity after doxorubicin treatment in cancer 
patients, and its combined use with doxorubicin was suggested to be a viable chemothera-
peutic modality that can selectively destroy tumors while concurrently limiting cardiac dam-
ages. Resveratrol was shown to mitigate the doxorubicin-induced cardiomyocyte apoptosis, 
autophagy, and fibrosis [15, 46].
Remote ischemic conditioning, a noninvasive nonpharmacological treatment delivered via a 
blood pressure cuff as short bursts of ischemia and reperfusion in a peripheral limb, with an 
unclear mechanism is a potentially cardioprotective treatment that is currently under inves-
tigation in cancer patients that may involve a humoral and neural pathway that confers car-
dioprotection by activating innate pro-survival pathways that ultimately modulate common 
Drug Induced Cardiotoxicity: Mechanism, Prevention and Management
http://dx.doi.org/10.5772/intechopen.79611
133
mechanisms in ischemia-reperfusion injury and anthracycline cardiotoxicity such as calcium 
overload, lipid peroxidation, ROS generation, and mitochondrial function [2].
6. Conclusion
Cardiotoxicity is an important dose-limiting side effect of various anticancer agents. In this 
chapter, we have identified some of the important and commonly used chemotherapeutic and 
biologic agents that have been reported to be associated with cardiovascular adverse effects. 
We have discussed the common mechanisms thought to be involved with such toxicity as well 
as the most important measures used to prevent and manage drug-induced cardiotoxicity. 
Although cardiotoxicity can occur without any predisposing factors, various risk factors are 
now known and considered of utmost importance to identify and manage before and during 
treatment, and we have discussed them. Finally, identifying drug-induced cardiac adverse 
effects as early as possible will help to prevent irreversible cardiac damage and to ameliorate 
the long-term morbidity and mortality rates as well as to improve the patients’ quality of life.
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